肥胖症药物初创公司Metsera(MTSR.US)盘前跌超2.2%，报79.71美元。该股昨日盘中一度大涨近16%，创下82.79美元的历史新高。 消息面上，知情人士透露，诺和诺德已再次提高对的收购出价，此举是回应辉瑞周三对Metsera的出价提高至每股最高86.2美元，与诺和诺德最近一次公开宣布的提议相当。 据悉，Metsera研发的新一代减重药物在中期临床试验中展现出良好耐受性，且减重效果可与者礼来的Zepbound相媲美。9月底披露的试验数据显示，受试者经过28周(每周注射一次)后，体重平均下降幅度达14.1%，恶心和呕吐发生率较低。(格隆汇)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.